Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Gynecologic Cancers
Interventions: Not listed
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Participants
Interventions: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Obesity, Overweight
Interventions: Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 25
States / cities: Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more

Conditions: Healthy
Interventions: Testosterone Enanthate, Dutasteride; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Diabetes
Interventions: Weight loss intervention; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes Mellitus, Insulin Dependent
Interventions: Intensive Home-Based Family Therapy, Supportive Telephone Calls; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Type 1 Diabetes
Interventions: Extended Wear Infusion Set, Standard Infusion Set; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
Interventions: MEDI3617, Bevacizumab, Paclitaxel, Carboplatin; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more

Conditions: Diabetes
Interventions: Contour® NEXT LINK BGMS, OneTouch® UltraLink® BGMS, Nova Max Link® BGMS; Device
Lead sponsor: Ascensia Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Mishawaka, Indiana

Conditions: Diabetes Mellitus, Type 1
Interventions: text message to parent only, text message to parent and adolescent; Other
Lead sponsor: University of Louisville; Other
Eligibility: 8 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Diabetes Mellitus, Type 2, PreDiabetes
Interventions: Morning Exercise, Afternoon Exercise; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: New Brunswick, New Jersey

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 85
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: IMNN-001, Carboplatin, Paclitaxel; Biological · Drug
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Mobile, Alabama • Newport Beach, California + 17 more

Conditions: Long COVID-19, Acute COVID-19, Postural Orthostatic Tachycardia Syndrome (POTS), Diabetic Neuropathy
Interventions: Not listed
Lead sponsor: CND Life Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Diabetic Foot
Interventions: Bluedrop Monitoring Service (BMS); Device
Lead sponsor: Bluedrop Medical Limited; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Type 2 Diabetes
Interventions: Orforglipron, Semaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 64
States / cities: Phoenix, Arizona • Canoga Park, California • Escondido, California + 58 more

Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Neratinib Maleate, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Lancaster, California + 13 more

Conditions: Endocrine Disorders
Interventions: Non intervention study; Other
Lead sponsor: Stanford University; Other
Eligibility: 3 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cardiovascular Diseases, Hypertension, Diabetes Type 2, Stroke, Recruitment, Overweight and Obesity, Hyperlipidemias
Interventions: EHR-informed Recruitment Method of Contact, Educational Text-Messages and Connection to Cardiovascular Research Opportunities; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 1
Interventions: Glargine, LY2605541, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 47
States / cities: Concord, California • Fresno, California • La Mesa, California + 44 more

Conditions: Diabetes, Gestational, Prediabetic State, Glucose Metabolism Disorders, Diabetes Mellitus
Interventions: Inpatient Postpartum GTT; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Inappropriate ADH Syndrome, Hyponatremia
Interventions: SR121463B; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Ovarian Cancer, Fibroids, Uterine Cancer
Interventions: Bupivacaine, Liposomal bupivacaine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Orange, California

Conditions: Ovarian Cancer
Interventions: Serial Transvaginal Ultrasonography; Procedure
Lead sponsor: John R van Nagell; Other
Eligibility: 24 Years and older · Female only
Enrollment: 65,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

The Role of 5-alpha Reductase in Mediating Testosterone Actions

Lifestyle Changes Through Exercise and Nutrition

Study of Intensive, Home-Based Family Therapy to Improve Illness Management in Youth With Diabetes

Evaluation of Extended Wear Infusion Set With 670G Hybrid Closed-Loop Therapy

A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors

Evaluation of Blood Glucose Monitoring Systems

The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes

Exercise and Time of Day in Type 2 Diabetes

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project

Remote Monitoring of the Diabetic Foot to Prevent Re-Ulceration

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Salivary Cortisol Measurements by Mass Spectrometry

Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)

A Study in Participants With Type I Diabetes Mellitus

Evaluating for Type-2 Diabetes in the Very Early Postpartum Period

Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer